CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression

CD19-specific chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable efficacy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) [1,2], and two anti-CD19 CAR-T cell products were approved by U.S. Food and Drug Administration for clinical use in 2017. However, a suitable target antigen for acute myeloid leukaemia (AML) or T-cell acute lymphoblastic leukaemia (T-ALL) has not been identified yet, although some preclinical studies and clinical trials have shown promising effects of CAR-T cell therapy against AML or T-ALL by targeting different antigens such as CD123, CD44v6, Lewis Y, FLT3 or CD7 [3,4].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research